Treatment of Crohn’s disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review by Changmei Hu et al.
CASE REPORT
Treatment of Crohn’s disease complicated with myelodysplastic
syndrome via allogeneic hematopoietic stem cell transplantation:
case report and literature review
Changmei Hu • Liang Lv •
Deliang Liu • Jirong Huo
Received: 31 October 2013 / Accepted: 7 May 2014 / Published online: 22 May 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Crohn’s disease (CD) is a chronic inflammatory
disease of the gastrointestinal tract arising in individuals
with genetic predisposing factors and abnormalities of the
immune system. Myelodysplastic syndrome (MDS), an
acquired clonal hematologic disorder, is characterized by
peripheral blood cytopenia, dysplastic changes in several
types of hematopoietic cells of the bone marrow and
peripheral blood, and a high risk of transformation to acute
leukemia. CD rarely occurs in combination with MDS, and
MDS treatment with hematopoietic stem cell transplanta-
tion (HSCT) has not been frequently reported. We report
the case of a 50-year-old Chinese male who presented with
abdominal pain, diarrhea, and fatigue. CD was diagnosed
by colonoscopy, imaging studies, and pathological exami-
nation. He was initially treated with mesalazine and pred-
nisone and thereafter he presented with pancytopenia.
MDS (RAEB-I) was diagnosed by bone marrow exami-
nation, and karyotyping revealed 47, XY, ?8. The patient
was treated with thalidomide, andriol, and decitabine.
Allogeneic HSCT was performed with a human leukocyte
antigen-matched sibling as the donor. The patient is cur-
rently well at 14 months after HSCT, without abdominal
pain, diarrhea, or fatigue. HSCT may be a promising
treatment option for patients with combined CD and MDS.
Keywords Crohn’s disease  Inflammatory bowel
disease  Myelodysplastic syndrome  Hematopoietic stem
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Introduction
Crohn’s disease (CD) is a chronic inflammatory disease of the
gastrointestinal (GI) tract arising in individuals with genetic
predisposing factors and abnormalities of the immune system. It
is characterized by periods of clinical relapse and remission, and
its incidence in the general population is 1–10/105. CD is a type
of inflammatory bowel disease (IBD). Although its etiology and
pathogenic mechanisms remain elusive, CD is thought to be
caused by the interaction of multiple environmental, genetic,
infectious, and immune factors.CD is frequently associated with
extraintestinal manifestations. Previous studies have shown that
the incidence of myelodysplastic syndrome (MDS) in patients
with IBD ranges from 170-550/105 [1, 2], which is higher than
seen in the general population. It has been suggested that an
association exists between CD and MDS. MDS, an acquired
clonal hematologic disorder, is characterized by peripheral
blood cytopenia, dysplastic changes in several types of hemo-
poietic cells in bone marrow and peripheral blood, and a high
risk of transformation to acute leukemia. MDS has been asso-
ciated with a variety of autoimmune phenomena, including
systemic vasculitis syndrome, seronegative arthritis, relapsing
polychondritis, etc. Some patients with MDS respond well to
immunosuppressive agents, including corticosteroids, cyclo-
sporine, and antithymocyte globulin [1]. CD rarely occurs in
combination with MDS and, therefore, treatment with hema-
topoietic stem cell transplantation (HSCT) is not common for
this condition. Here, we report the case of an adult patient with
CD and MDS who was treated with allogeneic HSCT.
Case presentation
A 50-year-old Chinese male who had been experiencing
persistent right lower abdominal pain, diarrhea, and fatigue
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for 6 months was admitted to our hospital. He occasionally
had mild fever. The patient lost approximately 10 kg of
weight over the 6-month period. He had a history of anal
fistula for [1 year. Physical examination results were
negative. A complete blood cell count analysis showed a
white blood cell count of 12.3 9 109/L, hemoglobin level
of 109 g/L, and platelet count of 237 9 109/L. The fecal
occult blood test was positive. Serum albumin was 30 g/L,
which was lower than the normal value. Barium enema
examination confirmed the presence of mucosal disorders.
Lesions showed segmental distribution. Colonoscopy
showed mucosal sheet erosion and congestion in the
ascending colon, with deep longitudinal ulcers, and double-
balloon enteroscopy showed multiple longitudinal ulcers in
the ileum (Figs. 1, 2). Imaging studies and pathological
examination indicated a predominance of inflammatory
cell invasion, and lymphoma was ruled out by immuno-
histochemical examination (Fig. 3) 1 month later. From
the disease history, and results of the various tests, we
confirmed a diagnosis of CD according to the diagnosis
consensus of CD in Japan [3]. The patient was initially
treated with mesalazine [1,000 mg, orally (PO), 4 times a
day] and his symptoms improved. Four months later,
prednisone was added [60 mg, (1 mg/kg PO), once a day]
to the treatment regimen, after which his symptoms
markedly improved. However, approximately 6 months
later, the patient presented with pancytopenia (white blood
cell count of 2.3 9 109/L, hemoglobin level of 65 g/L, and
platelet count of 55 9 109/L), dizziness, and serious fati-
gue. Bone marrow examination confirmed a diagnosis of
MDS (RAEB-I), and karyotyping revealed 47, XY, ?8
(Fig. 4). Thalidomide (200 mg, PO, once a day) and and-
riol (40 mg, PO, twice a day) were administered in addition
to mesalazine (1,000 mg, PO, once a day). The disease
showed no obvious improvement. The patient continued to
experience dizziness, fatigue, occasional abdominal pain,
and diarrhea. After 9 months, the need for transfusion
became evident, and the patient was started on induction
chemotherapy with decitabine (20 mg/m2 once a day for
5 days, 2 cycles), after which a complete response was
noted. Dizziness and fatigue significantly improved, but
occasional abdominal pain and diarrhea persisted.
Approximately 11 months after diagnosis, allogeneic
HSCT was performed with a human leukocyte antigen
(HLA)-matched sibling as the donor. The conditioning
regimen was cyclophosphamide 60 mg/kg once a day for
2 days, total body irradiation 10 Gy and rabbit anti-human
thymocyte globulin 2.5 mg/kg/days for 3 days. The bone
marrow was reconstituted by the infusion of an unselected
graft of 6.25 9 106/kg CD34-positive stem cells. At
16 days after HSCT, the patient’s white blood cell count
was [1.5 9 109/L, and at 19 days, his platelet count was
[20 9 109/L. Methotrexate and cyclosporin A were used
to prevent graft-versus-host disease. At 9 months after
HSCT, the patient discontinued all immunosuppressive
agents. At 14 months after HSCT, the patient was well
with no symptoms of abdominal pain, diarrhea, or fatigue,
and the anal fistula was cured. A chimerism study indicated
100 % donor chimerism at 25 months after diagnosis
(Table 1).
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Discussion
A thorough review of the recent literature revealed that
reports on CD combined with MDS treated with HSCT are
Fig. 1 Colonoscopy. Deep and longitudinal multiple ulcers were
observed at the colorectal mucosa. The mucosa plica between the
ulcers were normal
Fig. 2 Double-balloon enteroscopy
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extremely rare. One case of a 14-year-old male with CD
since the age of 8 years has been reported. He was first
administered prednisolone. After presenting with bloody
diarrhea, oral prednisolone was discontinued and 6-mer-
captopurine was commenced. Due to persistent diarrhea,
weekly anti-tumor necrosis factor alpha (TNF-a) was
started. The patient later became transfusion dependent and
bone marrow studies showed MDS-erythrodysplasia with
monosomy-7. Enzymatic studies confirmed TPMT hetero-
zygosity. In 2004, HLA-matched sibling transplantation
was performed. The patient is currently well 5 years and
8 months post-HSCT; his last chimerism study showed
100 % donor chimera [4]. Compared with our patient,
immunosuppressive treatments were observed in this
patient. In our case, the effects were not therapy related;
however, both patients received the same treatment post-
HSCT. To date, the mechanisms in both cases are unclear.
Fig. 3 Pathological finding of colonic biopsy specimen. A slit-like
ulcer reaching the muscularis propria was observed
Fig. 4 Karyotype analysis. A
47, XY, ?8 (20) karyotype was
observed
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The pathogenic mechanisms of CD complicated by
MDS are multiple, complex, and poorly understood. One
hypothesis is concerned with the common immunological
abnormalities. IBD is an autoimmune disease. Recent
evidence suggests that MDS is associated with autoimmune
diseases and carcinoid syndrome phenomena, such as
relapsed polychondritis, Sjo¨gren’s syndrome, rheumatoid
arthritis, CD, and multiple vasculitis, may be observed in
patients with MDS [2]. Patients with MDS also frequently
present with abnormalities of the immune system and show
a notable decrease in the T lymphocyte count. The Th1/
Th2 ratio is also increased in these patients, whereas the
counts and functions of CD8? lymphocytes, natural killer
cells, lymphokine-activated killer cells, and cytotoxic T
lymphocytes are all lower than the established normal
levels. In addition, lymphocytes secrete excessive amounts
of interleukin 1, interleukin 6, and TNF-a. These cytokines
play important roles in the pathogenesis of IBD. The pro-
duction of interleukin and TNF-a induced by inflammatory
reactions in patients with primary IBD may confer an
increased risk for the development of MDS [1, 5, 6].
The second hypothesis to explain the pathogenic
mechanism of CD complicated by MDS is based on
common chromosomal abnormalities. Several gene loci
have been used in the diagnosis of IBD, especially CD.
Mutations in the NOD2/CARD15 gene increase the risk of
CD development. Alleles that confer susceptibility (e.g.,
IL23R) have been identified, and IBD is known to be
associated with band 5q31 abnormalities on chromosome
5. Cytogenetic abnormalities in MDS have been exten-
sively studied, and these may be significant for diagnosis,
treatment, and prognostic evaluation. Although various
multiple detectable chromosomal abnormalities have been
described, the reported incidence of chromosomal abnor-
malities in patient with MDS combined with IBD is rela-
tively low. Furthermore, patients harboring chromosomal
abnormalities had a shorter interval between the develop-
ments of the 2 conditions than patients without chromo-
somal abnormalities [1, 2, 7]. Our patient showed a
chromosomal constitution of 47, XY, ?8, suggesting that
chromosomal abnormalities may be an important patho-
genic mechanism in the concomitant presentation of the 2
diseases. It is well known that trisomy 8 is a common
chromosomal abnormality in MDS. It often manifests as GI
lesions, including small bowel lesions [8].
Decreased phagocytosis of neutrophils in MDS patients
is the third hypothesis proposed to explain the pathogenic
mechanism of CD complicated by MDS. The use of iat-
rogenic immunosuppressant drugs in treatment of MDS
and IBD increases patient vulnerability to intestinal and
other infections and intestinal flora imbalance. Infection
has strongly been associated with the pathogenesis and
relapse of IBD and CD [9, 10].
HSCT is currently used for treatment of hematological
malignancies, but has also been tested for non-malignant
diseases and non-hematological diseases such as severe
refractory autoimmune diseases and solid tumors. Normal
hematopoietic stem cells are intravenously injected into the
patient and settle in the bone marrow. The patient’s
hematopoietic function is then restored through continuous
self-renewal and differentiation of hematopoietic stem
cells. This process may take 1-2 months, and the total
recovery of immune function may take up to 6 months to
1 year [11]. HSCT can therefore both reconstitute the
hematopoietic system and restore immune function.
Cases in which the pathogeneses of MDS and IBD are
attributable to common immunological and chromosomal
Fig. 5 Pathogenesis of Crohn’s disease and proposed advantage of
hematopoietic stem cell transplantation






D8S1179 12, 16 12, 13 12, 13
D21S11 29, 30 29, 29 29, 29
D7S820 11, 11 11, 11 11, 11
CSF1PO 11, 12 10, 12 10, 12
D3S1358 16, 17 14, 15 14, 15
TH01 6,10 9, 10 9, 10
D13S317 8, 8 8, 12 8, 12
D16S539 9, 9 12, 14 12, 14
D2S1338 19, 20 18, 23 18, 23
D19S433 14.2, 16.2 12,13.2 12, 13.2
VWA 14, 17 16, 18 16, 18
TPOX 8, 12 8, 8 8, 8
D18S51 14, 15 13, 19 13, 19
Amelogenin X, Y X, Y X, Y
D5S818 7, 12 10, 11 10, 11
FGA 21, 23 22, 25 22, 25
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abnormalities can theoretically be cured through immune
system reconstruction by HSCT, eliminating the need to
clone abnormal chromosomes. The application of HSCT in
the treatment of MDS is currently considered a sophisticated
technology [12, 13]. Both allogeneic and autologous HSCT
could effectively induce relief for patients in many severe
refractory autoimmune diseases, including IBD [14].
The putative mechanism underlying the effect of treat-
ment of IBD with HSCT is shown in Fig. 5.
Allogeneic HSCT may replace all recipient hemolym-
phatic cells with donor hemolymphatic cells harboring
DNA sequences that do not predispose to CD, thereby
alleviating CD. Autologous HSCT may replace hem-
olymphatic cells or their progenitor cells that generated the
predisposing DNA sequence during ontogeny (e.g., T cell
clones capable of recognizing the peptide) with healthy
autologous hemolymphatic cells (e.g., T cell clones gen-
erated de novo in the thymus after HSCT that cannot rec-
ognize the peptide), thereby alleviating CD [14, 15]. The
proposed mechanisms of autologous HSCT in the treatment
of autoimmune diseases include immune suppression,
immune resetting via repertoire replacement, and immune
resetting via restoration of immune regulation [16]. Our
patient with CD complicated by MDS showed satisfactory
outcomes with allogeneic HSCT treatment.
Conclusion
Several recent reports have described the favorable effects
of HSCT in the treatment of patients with severe CD,
including those with concomitant MDS [17–20]. Thus,
HSCT may be a promising treatment option for patients
with combined CD and MDS.
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